
- BioPharm International-10-15-2016
- Volume 2016 eBook
- Issue 2
Cell Line Quality Technologies
BioPharm International spoke with Selexis CEO and Chairman Igor Fisch, PhD about the latest cell-line development advances.
Chinese hamster ovary (CHO) cells are a common and stable option for mammalian expression systems, but what are the other cell line options in upstream processing and how do they compare in quality and stability to CHO cells? And what are the best techniques for ensuring quality and stability in cell-line development? BioPharm International spoke with Selexis CEO and Chairman Igor Fisch, PhD about the latest cell-line development advances and the analytical techniques companies can use to ensure quality and stability.
Download the BioPharm International
.
Articles in this issue
almost 9 years ago
Investigation Effectiveness Drives Human Performance Excellencealmost 9 years ago
Data Integrity Challenges in Manufacturingalmost 9 years ago
Evaluating Technology and Innovation in Biopharmaceutical Manufacturingalmost 9 years ago
Seeking Accelerated Biosimilar Characterizationalmost 9 years ago
Plant-Made Pharmaceuticals—Accelerating Drug Development Globallyalmost 9 years ago
Testing the BrothNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.